FITLIFE BRANDS, INC. FTLF
Nasdaq · XNAS · stock · Medicinal Chemicals & Botanical Products
Chart by TradingView
3/9
Piotroski F — financial health
1.99
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $15.9M | $2.0M | $6.9M | $7.4M | $43.6M |
| 2024 | $64.5M | $9.0M | $28.1M | $9.6M | $36.1M |
| 2023 | $52.7M | $5.3M | $21.4M | $4.1M | $27.0M |
| 2022 | $28.8M | $4.4M | $12.0M | $4.1M | $21.4M |
| 2021 | $27.9M | $5.4M | $12.5M | — | $17.3M |
| 2020 | $22.1M | $8.8M | $9.5M | — | $11.9M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 1.99 (grey)
- Working capital / assets 0.108
- Retained earnings / assets 0.112
- EBIT / assets 0.028
- Equity / liabilities 0.696
Source: SEC EDGAR filings · CIK 0001374328 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.